Evidence map›Paper›PMID 35482079›Full record

Trial reportJournal of neurology2022

MemAID: Memory advancement with intranasal insulin vs. placebo in type 2 diabetes and control participants: a randomized clinical trial.

Vera Novak, Christos S Mantzoros, Peter Novak, Regina McGlinchey, Weiying Dai, Vasileios Lioutas, Stephanie Buss, Catherine B Fortier, Faizan Khan, Laura Aponte Becerra and 1 more

2 registry-linked trialsOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 33 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06072963 phase2recruitingstarted 2024, after this paper: background citation

Combination of Intranasal Insulin With Oral Semaglutide to Improve Cognition and Cerebral Blood Flow: a Feasibility Study

Ran2024Enrolled80Registered outcomes15Posted comparisons0ConditionsAlzheimer Disease, Metabolic Syndrome, Mild Cognitive ImpairmentArmsIntranasal insulin, Intranasal insulin placebo, semaglutide, Semaglutide placebo
PMID 36871874PMID 29687620PMID 3662782PMID 8563978PMID 9191756PMID 32982937PMID 33044181PMID 18430999PMID 32568367PMID 32716707PMID 32562683PMID 32296731other papers from this trial
Open the trial in the graph
NCT02415556 phase2completednot on this map

Memory Advancement by Intranasal Insulin in Type 2 Diabetes

TypeinterventionalSponsorBeth Israel Deaconess Medical CenterRan2015 to 2020Enrolled289ConditionsType 2 Diabetes MellitusArmsRegular Human Insulin, Placebo
3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Intranasal insulin for improving cognitive function in multiple sclerosis.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Vera NovakDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Boston, MA, 02215, USA. vnovak@bidmc.harvard.edu.ORCID http://orcid.org/0000-0001-9773-1966
Christos S MantzorosDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.
Peter NovakDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Regina McGlincheyTranslational Research Center for TBI and Stress Disorders (TRACTS) and Geriatric Research Educational and Clinical Research Center (GRECC), VA Boston Healthcare System, Boston, MA, USA.
Weiying DaiDepartment of Computer Science, State University of New York (SUNY), Binghamton, NY, USA.
Vasileios LioutasDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Boston, MA, 02215, USA.
Stephanie BussDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Boston, MA, 02215, USA.
Catherine B FortierTranslational Research Center for TBI and Stress Disorders (TRACTS) and Geriatric Research Educational and Clinical Research Center (GRECC), VA Boston Healthcare System, Boston, MA, USA.
Faizan KhanDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Boston, MA, 02215, USA.
Laura Aponte BecerraDepartment of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, 185 Pilgrim Rd, Boston, MA, 02215, USA.
Long H NgoDepartment of Medicine, Beth Israel Deaconess Medical Center and School of Public Health, Harvard Medical School, Boston, MA, USA.
Beth Israel Deaconess Medical Center · USHarvard University · USBinghamton University · USBrigham and Women's Hospital · US

Funding

Understanding the structural, functional, and prognostic implications of cortical excitability in Alzheimer's diseaseK23AG068364 · BETH ISRAEL DEACONESS MEDICAL CENTER · 2025 to 2025
$240k
EPA EP-C-15-031NCATS NIH HHS UL1 TR002541NIA NIH HHS K23 AG068364NIDDK NIH HHS R01 DK103902
6 · The paper itself

Abstract

backgroundThis study aimed at assessing the long-term effects of intranasal insulin (INI) on cognition and gait in older people with and without type 2 diabetes mellitus (T2DM).

methodsPhase 2 randomized, double-blinded trial consisted of 24 week treatment with 40 IU of INI (Novolin

resultsDM-INI had faster NW (~ 7 cm/s; p = 0.025) and DTW on-treatment (p = 0.007; p = 0.812 adjusted for baseline difference) than DM-Placebo. Control-INI had better executive functioning on-treatment (p = 0.008) and post-treatment (p = 0.007) and verbal memory post-treatment (p = 0.004) than Control-Placebo. DM-INI increased cerebral blood flow in medio-prefrontal cortex (p < 0.001) on MRI. Better vasoreactivity was associated with faster DTW (p < 0.008). In DM-INI, plasma insulin (p = 0.006) and HOMA-IR (p < 0.013) decreased post-treatment. Overall INI effect demonstrated faster walking (p = 0.002) and better executive function (p = 0.002) and verbal memory (p = 0.02) (combined DM-INI and Control-INI cohort, hemoglobin A1c-adjusted). INI was not associated with serious adverse events, hypoglycemic episodes, or weight gain.

conclusionThere is evidence for positive INI effects on cognition and gait. INI-treated T2DM participants walked faster, showed increased cerebral blood flow and decreased plasma insulin, while controls improved executive functioning and verbal memory. The MemAID trial provides proof-of-concept for preliminary safety and efficacy and supports future evaluation of INI role to treat T2DM and age-related functional decline.

Indexed as

Diabetes Mellitus, Type 2InsulinAdministration, IntranasalAgedAged, 80 and overBlood GlucoseDouble-Blind MethodFemaleGlycated HemoglobinHumansHypoglycemic AgentsMaleMiddle AgedBlood GlucoseGlycated HemoglobinHypoglycemic AgentsInsulinAgingBrain blood flowCognitionGaitIntranasal insulinType 2 diabetes

Identifiers

PMID35482079
PMCPMC9046533
OpenAlexW4225009808

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.